)
Edge1 May 2026
Making the Marlboro Man
The story of Marlboro's transformation from a women's cigarette to a global icon: one of the most effective brand repositionings in history.
Apimeds Pharmaceuticals
Apimeds Pharmaceuticals (APUS) investor relations material
Apimeds Pharmaceuticals has been acquired
Apimeds Pharmaceuticals Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary4 May, 2026
Executive summary
Fiscal year 2025 marked a transformation with an IPO and the acquisition of MindWave Innovations, adding a digital asset segment to the biopharmaceutical business.
The company operates two segments: biopharmaceuticals (Apitox for knee osteoarthritis) and digital asset operations (MindWaveDAO, holding BTC, USDT, and NILA Tokens).
No revenue was generated from biopharmaceutical or digital asset operations in 2025; digital asset gains were recognized as other income.
Financial highlights
Net loss for 2025 was $6.0 million, up from $1.4 million in 2024, driven by increased R&D and G&A expenses.
Total operating expenses rose to $11.9 million in 2025 from $1.3 million in 2024.
Other income of $5.9 million in 2025 was primarily from digital asset gains post-MindWave acquisition.
Cash and equivalents at year-end 2025 were $1.6 million, with $8.0 million in restricted cash and $2.0 million in short-term investments.
Digital assets at fair value totaled $149.9 million as of December 31, 2025.
Outlook and guidance
The company expects continued operating losses as it advances Apitox clinical development and builds operational infrastructure.
Significant manufacturing costs for Apitox are anticipated in 2026.
Management plans to address liquidity needs through additional convertible note tranches, NILA Token sales, and potential equity or debt financing.
Address FDA concerns in the new Phase III trial
Strategy for Bitcoin reserves and NILA liquidity
Plan to release $8 million in restricted cash
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Apimeds Pharmaceuticals
- IPO aims to fund late-stage trials for a novel bee venom therapy, but risks remain high.APUS
Registration Filing29 Nov 2025 - IPO funds Phase III trials for novel OA/MS therapy; high risk, no revenue, major owner controls.APUSRegistration Filing29 Nov 2025
- IPO aims to fund late-stage trials for a novel bee venom therapy targeting OA and MS.APUSRegistration Filing29 Nov 2025
- IPO funds will advance Apitox clinical trials for OA and MS amid high risk and no revenue.APUSRegistration Filing29 Nov 2025
- IPO funds pivotal Apitox trials for OA/MS; no US revenue, high risk, major shareholder control.APUSRegistration Filing29 Nov 2025
- IPO targets $16.1M to fund Phase III OA trial for bee venom therapy; high risk, no revenue.APUSRegistration Filing29 Nov 2025
- IPO aims to fund U.S. trials for bee venom therapy; high risk, no revenue, majority control.APUSRegistration Filing29 Nov 2025
- IPO aims to fund late-stage trials for a novel bee venom therapy in OA and MS.APUSRegistration Filing29 Nov 2025
- Q3 2025 net loss rose to $1.78M as R&D and G&A costs surged post-IPO; cash runway extends 12 months.APUSQ3 202512 Nov 2025
Apimeds Pharmaceuticals
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage